Company: PTPI
Filing Date: 2025-02-14
Form Type: CORRESP
Source: 0001104659-25-013915
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: CORRESP
Chunk 0
---
<div align='center'>Dawson James Securities, Inc.

101 North Federal Highway, Suite 600

Boca Raton, Fl 33432</div>

February 14, 2025

VIA EDGAR CORRESPONDENCE

| U.S. Securities and Exchange Commission 
 Division of Corporation Finance         
 100 F Street, N.E.                      
 Washington, D.C. 20549                  |

| Re: | Petros Pharmaceuticals, Inc.         
 Registration Statement on Form S-1/A 
 File No. 333-284495                  |

Ladies and Gentlemen:

Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent,
hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced
registration statement on Form S-1/A (the “Registration Statement”) to become effective at 4:00 p.m., Eastern Time, on
Friday, February 14, 2025 or as soon thereafter as practicable.

Pursuant to Rule 460
under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated February 14, 2025,
to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as placement
agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

If you require any additional
information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

| Very truly yours,             |                         |
| DAWSON JAMES SECURITIES, INC. |                         |
| By:                           | /s/                     
 Robert D. Keyser, Jr.   |
|                               | Robert D. Keyser, Jr.   |
|                               | Chief Executive Officer |

| cc: | M. Ali Panjwani, Esq. |

| Pryor Cashman LLP |